Multivariable analysis of prognostic factors for relapsed or refractory ML-DS
| Variable . | n 61 . | Overall survival . | Event-free survival . | ||
|---|---|---|---|---|---|
| HR (95% CI) . | P . | HR (95% CI) . | P . | ||
| Duration of CR1 | .029 | .013 | |||
| 1 d–5.99 mo | 29 | ref | ref | ||
| 6-12 mo | 18 | 0.49 (0.24-0.99) | 0.40 (0.20-0.83) | ||
| >12 mo | 5 | 0.31 (0.09-1.06) | 0.28 (0.08-0.95) | ||
| 0 (refractory) | 9 | 0.38 (0.16-0.89) | 0.36 (0.15-0.86) | ||
| Treated with HSCT | <.001 | .002 | |||
| No | 32 | ref | ref | ||
| Yes | 29 | 0.28 (0.14-0.54) | 0.35 (0.18-0.69) | ||
| Achieved second remission after treatment for first relapse | <.001 | <.001 | |||
| Yes | 27 | ref | ref | ||
| No | 34 | 4.03 (1.93-8.41) | 3.58 (1.68-7.62) | ||
| Variable . | n 61 . | Overall survival . | Event-free survival . | ||
|---|---|---|---|---|---|
| HR (95% CI) . | P . | HR (95% CI) . | P . | ||
| Duration of CR1 | .029 | .013 | |||
| 1 d–5.99 mo | 29 | ref | ref | ||
| 6-12 mo | 18 | 0.49 (0.24-0.99) | 0.40 (0.20-0.83) | ||
| >12 mo | 5 | 0.31 (0.09-1.06) | 0.28 (0.08-0.95) | ||
| 0 (refractory) | 9 | 0.38 (0.16-0.89) | 0.36 (0.15-0.86) | ||
| Treated with HSCT | <.001 | .002 | |||
| No | 32 | ref | ref | ||
| Yes | 29 | 0.28 (0.14-0.54) | 0.35 (0.18-0.69) | ||
| Achieved second remission after treatment for first relapse | <.001 | <.001 | |||
| Yes | 27 | ref | ref | ||
| No | 34 | 4.03 (1.93-8.41) | 3.58 (1.68-7.62) | ||
REF reference value.